BioAge Labs: Auditing The Telomere Cliff
**Auditing the Telomere Cliff** Join Marcus and Katie as they initiate the TELOMERE CLIFF Archive, dissecting BioAge Labs' ambitious Q1 2026 public offering and the unsettling implications for the future of human longevity. Marcus, ever the cynic, labels BioAge's $115 million venture a "biological payday loan," questioning the transparency of their finances and the true cost of delaying inevitable decay. Katie, with her clinical precision, presents the data on Azelaprag (BGE-102) and its purported 86% reduction in inflammatory markers, but even her meticulously sourced figures can't mask the…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.